The ASGCT’s Q1 2026 Landscape Report highlighted a growing gene-, cell-, and RNA-therapy pipeline alongside increased startup funding. ASGCT CEO David Barrett said 42 gene therapies and 38 RNA therapies are approved worldwide, with 76 non-genetically modified cell therapies also approved, and that deal-making saw a modest increase. Barrett pointed to a 30% increase in startup funding versus Q1 2025, alongside regulatory pace improvement, including eight gene therapy approvals over the prior 12 months. In gene therapy, he reported 350 Phase I, 319 Phase II, and 41 Phase III trials, with an increasing share focused on non-oncology indications. In RNA therapies, Barrett said RNAi programs are gaining attention and growth, while mRNA remains less active relative to earlier bursts. For industry participants, the report functions as an industry scorecard for where approvals, clinical-stage activity, and capital formation are concentrating—especially in modalities that depend on manufacturing scale and regulatory decision cycles.